Felzartamab, an investigational anti-CD38 monoclonal antibody, is a potentially differentiated therapeutic candidate with promise for a broad range of immune-mediated diseases ...

-- RBT-101, Radiant's lead oncology program and 4-1BB agonist, demonstrated robust, durable and complete tumor regression without liver toxicity in MC38 colorectal mouse tumor model -- Poster ...

Our latest Focus Issue looks at what we’ve learnt over the past decade and what’s next for the field of trained immunity.

HCB301 is a first-in-class tri-specific immunotherapy targeting SIRPα-CD47, PD-1/PD-L1, and TGFβ; it shows potent macrophage activation, T-cell restoration, and tumor microenvironment remodeling in ...

London, 5 November 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in ...